WO2006052773A3 - Traitement pour des affections demyelinisantes a mediation immunitaire - Google Patents

Traitement pour des affections demyelinisantes a mediation immunitaire Download PDF

Info

Publication number
WO2006052773A3
WO2006052773A3 PCT/US2005/040070 US2005040070W WO2006052773A3 WO 2006052773 A3 WO2006052773 A3 WO 2006052773A3 US 2005040070 W US2005040070 W US 2005040070W WO 2006052773 A3 WO2006052773 A3 WO 2006052773A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatments
mediated diseases
immune mediated
demyelinating
demyelinating immune
Prior art date
Application number
PCT/US2005/040070
Other languages
English (en)
Other versions
WO2006052773A2 (fr
Inventor
Rosario Billetta
Igor Bilinsky
Original Assignee
Androclus Therapeutics Inc
Rosario Billetta
Igor Bilinsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Androclus Therapeutics Inc, Rosario Billetta, Igor Bilinsky filed Critical Androclus Therapeutics Inc
Publication of WO2006052773A2 publication Critical patent/WO2006052773A2/fr
Publication of WO2006052773A3 publication Critical patent/WO2006052773A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions et procédés pour réaliser des thérapies combinées pour le traitement d'affections démyélinisantes, et en particulier de la sclérose en plaques.
PCT/US2005/040070 2004-11-07 2005-11-04 Traitement pour des affections demyelinisantes a mediation immunitaire WO2006052773A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62590404P 2004-11-07 2004-11-07
US62614304P 2004-11-07 2004-11-07
US60/626,143 2004-11-07
US60/625,904 2004-11-07

Publications (2)

Publication Number Publication Date
WO2006052773A2 WO2006052773A2 (fr) 2006-05-18
WO2006052773A3 true WO2006052773A3 (fr) 2007-04-26

Family

ID=36337007

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/040070 WO2006052773A2 (fr) 2004-11-07 2005-11-04 Traitement pour des affections demyelinisantes a mediation immunitaire
PCT/US2005/039789 WO2006052654A2 (fr) 2004-11-07 2005-11-04 Compositions et procedes pour le traitement de maladies a mediation immunitaire

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2005/039789 WO2006052654A2 (fr) 2004-11-07 2005-11-04 Compositions et procedes pour le traitement de maladies a mediation immunitaire

Country Status (1)

Country Link
WO (2) WO2006052773A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4264257B2 (ja) * 2000-11-01 2009-05-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 熱ショックタンパク質に由来する免疫調節ペプチドとその使用
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MILLER D.H.: "Colloquium C15: Natalizumab (anti-VLA4 antibody) in multiple sclerosis", JOURNAL OF NEUROCHEMISTRY, vol. 85, no. SUPPL. 1, 2003, pages 96, C15-04, XP003009634 *

Also Published As

Publication number Publication date
WO2006052654A2 (fr) 2006-05-18
WO2006052654A3 (fr) 2007-11-15
WO2006052773A2 (fr) 2006-05-18

Similar Documents

Publication Publication Date Title
WO2006023649A3 (fr) Traitement de la sclerose en plaques grave
WO2007024705A3 (fr) Procede de traitement de la depression au moyen d'un anticorps anti-tnf-alpha
WO2005055932A3 (fr) Combinaisons therapeutiques et methodes faisant appel a des composes irm
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2004041170A9 (fr) Compositions et methodes pour le traitement de maladies liees au systeme immunitaire
WO2007044026A3 (fr) Compositions comportant du collagène modifié et leurs utilisations
AU2003297684A1 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2005118511A3 (fr) Composes, compositions et methodes permettant de stabiliser la transthyretine et d'inhiber un mauvais repliement de la transthyretine
WO2005027966A3 (fr) Anticorps aux fonctions d'effecteur modifiees
WO2008050148A3 (fr) Thérapie pour une maladie du foie
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
WO2006002437A3 (fr) Traitement d'etats pathologiques impliquant la demyelinisation
WO2006055871A3 (fr) Traitement de la sclerose en plaques
WO2007056540A3 (fr) Traitement anti-tnf$g(a) destine a traiter l'enterocolite associee a un traitement par anticorps therapeutique immunostimulateur
WO2005044093A3 (fr) Compositions de delta-9-thc et methodes de traitement de symptomes lies la sclerose en plaques
WO2007047608A3 (fr) Substances therapeutiques ciblees sur la fibrine
WO2003099217A3 (fr) Methodes de traitement d'infections bacteriennes et de maladies associees
WO2005085188A3 (fr) Composes et procedes pour la therapie antitumorale
WO2008029169A3 (fr) Procédé de traitement de troubles respiratoires
WO2007146335A3 (fr) Composés et compositions pour le traitement du cancer
WO2006020430A8 (fr) Nouvelle composition et procedes destines au traitement d'une maladie immunitaire
WO2006078336A3 (fr) Compositions et methodes permettant de traiter et de prevenir des maladies hyperproliferatives
WO2005011605A3 (fr) Polytherapies pour la sclerose en plaques
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
WO2006024958A3 (fr) Compositions cannabinoides et procedes d'utilisation correspondants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05823410

Country of ref document: EP

Kind code of ref document: A2